Slingshot Insights | Rlmd Overview

RLMD Overview

Upcoming Projects (RLMD)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (RLMD)

Looking at the Phase 3 Long-Term study of Relmada Therapeutics' novel NMDAR channel blocker, REL-1017, for treatment of major depressive disorder.
Ticker: RLMD
Executed On: Oct 03, 2023 at 12:15 PM EDT
2 Week Delay: Opioid Addiction and Methadone Hydrochloride Survey
Ticker: RLMD
Executed On: Oct 26, 2022 at 11:25 AM EDT
A second look at REL-1017 ahead of the RELIANCE III results
Ticker: RLMD
Executed On: Jul 26, 2022 at 04:00 PM EDT
A look at REL-1017 ahead of the RELIANCE III results
Ticker: RLMD
Executed On: Jul 19, 2022 at 04:00 PM EDT
Looking at the potential of REL-1017 in treating Depression ahead of multiple Phase 3 readouts in 2022.
Tickers: RLMD, AXSM, SAGE, BTAI, XENE
Executed On: Apr 07, 2022 at 03:30 PM EDT

Upcoming & Overdue Catalysts (RLMD)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (RLMD)

Relmada Stockholders Elect All of the Company's Director Nominees, after CFO Beck left the company; results will be made available on Form 8-K and filed with the SEC
Ticker: RLMD
Occurred on: Dec 30, 2015

Strategic Initiatives (RLMD)

Don’t see a strategic initiative related to the company you care about? Create your own!